ICU Medical Inc. (NASDAQ:ICUI) Director Robert S. Swinney sold 2,025 shares of the business’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $142.88, for a total value of $289,332.00. Following the sale, the director now directly owns 16,850 shares of the company’s stock, valued at $2,407,528. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

ICU Medical Inc. (NASDAQ:ICUI) opened at 144.60 on Thursday. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of 41.70 and a beta of 0.30. ICU Medical Inc. has a 12-month low of $85.56 and a 12-month high of $154.80. The stock has a 50 day moving average price of $141.00 and a 200 day moving average price of $120.75.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $1.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.17 by $0.18. ICU Medical had a net margin of 15.18% and a return on equity of 10.70%. The business earned $97.11 million during the quarter, compared to analyst estimates of $93.04 million. During the same period last year, the business posted $1.00 earnings per share. ICU Medical’s quarterly revenue was up 12.9% compared to the same quarter last year. On average, analysts expect that ICU Medical Inc. will post $4.79 EPS for the current year.

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

A number of hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. raised its stake in shares of ICU Medical by 69.3% in the second quarter. Victory Capital Management Inc. now owns 366,618 shares of the company’s stock valued at $41,336,000 after buying an additional 150,066 shares during the period. JPMorgan Chase & Co. raised its stake in shares of ICU Medical by 67.5% in the second quarter. JPMorgan Chase & Co. now owns 309,998 shares of the company’s stock valued at $34,953,000 after buying an additional 124,920 shares during the period. Royal Bank of Canada raised its stake in shares of ICU Medical by 1,469.8% in the first quarter. Royal Bank of Canada now owns 131,830 shares of the company’s stock valued at $13,725,000 after buying an additional 123,432 shares during the period. Champlain Investment Partners LLC raised its stake in shares of ICU Medical by 19.8% in the second quarter. Champlain Investment Partners LLC now owns 479,060 shares of the company’s stock valued at $54,014,000 after buying an additional 79,235 shares during the period. Finally, BlackRock Fund Advisors raised its stake in shares of ICU Medical by 8.0% in the third quarter. BlackRock Fund Advisors now owns 1,006,142 shares of the company’s stock valued at $127,156,000 after buying an additional 74,697 shares during the period. Institutional investors and hedge funds own 89.04% of the company’s stock.

A number of analysts have commented on the company. Zacks Investment Research lowered ICU Medical from a “buy” rating to a “hold” rating in a report on Wednesday, November 2nd. Piper Jaffray Cos. reaffirmed a “neutral” rating and issued a $119.00 target price (up from $115.00) on shares of ICU Medical in a report on Thursday, August 11th.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

5 Day Chart for NASDAQ:ICUI

Receive News & Stock Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related stocks with our FREE daily email newsletter.